These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17068390)

  • 21. News on bisphosphonates: but will patterns of use change?
    Garg A
    Dent Implantol Update; 2010 Sep; 21(9):71-2. PubMed ID: 20863016
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
    von Moos R; Caspar CB; Steiner R; Angst R; Inauen R; Schmieding K; Thürlimann B
    Onkologie; 2010; 33(8-9):447-50. PubMed ID: 20838060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonate-associated adverse events.
    Papapetrou PD
    Hormones (Athens); 2009; 8(2):96-110. PubMed ID: 19570737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Care required when using bisphosphonates in dental surgical practice.
    Goiato MC; dos Santos DM; Rondon BC; Moreno A; Baptista GT; Verri FR; Dekon SF
    J Craniofac Surg; 2010 Nov; 21(6):1966-70. PubMed ID: 21119471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tooth extraction: Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates?
    Altundag K; Bulut N; Tezcan E; Ozen M; Purnak T
    J Oral Maxillofac Surg; 2007 Jan; 65(1):154. PubMed ID: 17174785
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling the safety and tolerability of bisphosphonates.
    Body JJ; Diel I; Bell R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):73-8. PubMed ID: 15490380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal complications from bisphosphonate treatment.
    Hirschberg R
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):342-7. PubMed ID: 22710581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function.
    Bergner R; Henrich DM; Hoffmann M; Honecker A; Mikus G; Nauth B; Nagel D; Uppenkamp M
    J Clin Pharmacol; 2007 Aug; 47(8):942-50. PubMed ID: 17615253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of the adverse effects associated with intravenous bisphosphonates.
    Tanvetyanon T; Stiff PJ
    Ann Oncol; 2006 Jun; 17(6):897-907. PubMed ID: 16547070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis.
    Lewiecki EM; Miller PD
    Expert Opin Drug Saf; 2007 Nov; 6(6):663-72. PubMed ID: 17967155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute renal effects of intravenous bisphosphonates in the rat.
    Pfister T; Atzpodien E; Bohrmann B; Bauss F
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):374-81. PubMed ID: 16364053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of multiple myeloma bone disease: impact of treatment on renal function.
    Kanellias N; Gavriatopoulou M; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2018 Nov; 11(11):881-888. PubMed ID: 30285492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scleritis and Intraorbital Inflammation following Oral and Intravenous Bisphosphonates in a 66-Year-Old Man.
    Heck K; Malinina S; Palmowski A
    Klin Monbl Augenheilkd; 2024 Apr; 241(4):426-428. PubMed ID: 38653272
    [No Abstract]   [Full Text] [Related]  

  • 39. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.
    Pfister T; Atzpodien E; Bauss F
    Toxicology; 2003 Sep; 191(2-3):159-67. PubMed ID: 12965119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrotoxicity of third-generation, intravenous bisphosphonates.
    Hirschberg R
    Toxicology; 2004 Mar; 196(1-2):165-7; author reply 169-70. PubMed ID: 15036766
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.